The results come from five patients enrolled in the biotech's ingoing phase ... treat MPS I include Immusoft and Sigilon Therapeutics, which are developing cell-based therapies for the disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback